Skip to main content
Industry News
Apabetalone does not lower CV risk in patients with T2D, ACS

Investigational drug apabetalone, a BET protein inhibitor, was not effective compared with placebo in lowering adverse cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome at 26 months. The study, presented at the American Heart Association meeting, used data from 2,418 patients and found that 10.3% of those taking apabetalone experienced CV death, non-fatal myocardial infarction or stroke, compared with the 12.4% of patients who were taking placebo.

Full Story: